OpenLegislation

Division 3.4.2.1.3.1 F1F2

United Kingdom

Original text. Later amendments are not shown.

Data from appropriate animal studies f1 which may be indicative of the potential of a substance to cause sensitisation by inhalation in humans f2 may include:

  1. (a)

    measurements of Immunoglobulin E (IgE) and other specific immunological parameters, for example in mice;

  2. (b)

    specific pulmonary responses in guinea pigs.

Annotations

Textual amendments

F1

Substituted by Commission Regulation (EU) No 286/2011 of 10 March 2011 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (Text with EEA relevance).

F2

Substituted by Commission Regulation (EU) 2019/521 of 27 March 2019 amending, for the purposes of its adaptation to technical and scientific progress Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (Text with EEA relevance).

Footnotes

f1

At present, recognised and validated animal models for the testing of respiratory hypersensitivity are not available. Under certain circumstances, data from animal studies may provide valuable information in a weight of evidence assessment.

f2

The mechanisms by which substances induce symptoms of asthma are not yet fully known. For preventative measures, these substances are considered respiratory sensitisers. However, if on the basis of the evidence, it can be demonstrated that these substances induce symptoms of asthma by irritation only in people with bronchial hyper-reactivity, they shall not be considered as respiratory sensitisers .